Treatment of Adults with Clostridioides Difficile Infection

Treatment of Adults with Clostridioides Difficile Infection using CRS3123 compared to Vancomycin

Clostridioides difficile (CDI) is a type of bacteria, which lives in the intestines of many people and animals and is also present in the environment in places such as soil and water. When the intestinal microflora is out of balance, the C. difficile bacteria

begin to grow and produce toxins causing diarrhea and other symptoms such as abdominal pain or tenderness, loss of appetite, low-grade fever, nausea, and vomiting. Sometimes CDI can become severe causing bloody diarrhea and even death. Napa Research has a clinical research study aimed at treating CDI more effectively than standard vancomycin.

The study medication active molecules:

CRS3123 is an antibiotic study treatment with a new way of attacking the

bacteria that cause CDI, Vancomycin

Mode of administration:

Medication will be given orally, 4 times daily for 10 days

The study duration: 70 days

Participants will attend 8 study site visits and receive follow-up checks following the completion of the study.

Compensation package includes:

$75.00 for each visit

$38.00 for each telephone contact

All study medication, assessments and examinations are free to the participants.

Inclusion Questions:

Has the patient ever been diagnosed with CDI?

Is the patient experiencing diarrhea symptoms?

Is the patient experiencing any stomachache or vomiting?

Patient’s other medical conditions: